Genenta Announces Nomination of Mark A. Sirgo as Chair
35 years industry experience including as CEO and founder of public company
Pierluigi Paracchi, CEO of Genenta, said: "I am delighted to welcome Mark to Genenta as our nominated new Chair. Mark brings exhaustive experience of all aspects of drug and company development, from R&D to raising financing to sales and marketing. His expertise will be invaluable to Genenta as we continue the development of our proprietary stem cell gene therapy Temferon™ through clinical trials and towards market."
"I would like to thank Steve for his outstanding contribution to Genenta over the last 18 months. He has helped to lead us through an important stage of development, both in terms of the business and clinical development of Temferon™, including our successful upsized initial public offering on Nasdaq. I would like to wish Steve all the best for his future role."
In connection with Dr. Squinto’s departure and considering his contribution in the completion of the IPO process, the
About
Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). Temferon™, which is under investigation in a phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is designed to reach solid tumors, induce a durable immune response not restricted to pre-selected tumor antigens nor type, and avoid systemic toxicity, which are some of the main unresolved challenges in immuno-oncology.
Investor Relations - |
Genenta Media Contact |
+44 7483 28 48 53 | +39 3482315143 |
mchang@lifesciadvisors.com | tiziana.pollio@genenta.com |
Source: Genenta Science